Full Press Release Details
Lexaria Proposes to Change Name to Lexaria Bioscience Corp
Kelowna, BC / February 19, 2016 / Lexaria, Corp. (OTCQB:LXRP)
(CSE:LXX) (the Company ) announces that at the Annual General Meeting expected
to be held March 23, 2016, the Company proposes to change its name to Lexaria
The Company has had its current name since 2004 but has
undergone a remarkable transformation in the last two years to become a
bioscience company with a suite of patents pending in the field of active
molecule delivery through common foods. This technology has broad application
throughout the food industry with regards to several beneficial molecules such
as common over-the-counter pain medications as well as vitamins and more.
In December 2015 Lexaria filed two new provisional patent
applications related to the utilization of its food enhancement and molecule
cloaking technology across a broad spectrum of commercially prepared foods such
as many forms of snacks, breads, baked goods of all kinds, bottled drinks,
juices and much more. The underlying technology was originally uncovered by the
PhD researcher/founder of PoViva Tea LLC investigating methodologies for
improving cannabinoid absorption and has since been significantly broadened in
scope by Lexaria s executive team.
Lexaria s technology allows for near-pharma grade liposomal
encapsulation of payload molecules - such as acetaminophen, ibuprofen,
cannabinoids and much more within trojan horse foods. The technology greatly
improves flavor while simultaneously enhancing bioabsorption of the payload
molecules. In light of the significant progress made through 2015 and already in
2016 with the understanding of commercial applications for these scientific
discoveries, the change in name to Lexaria Bioscience Corp. seems entirely
The Company has enjoyed a loyal and dedicated shareholder base
and business network whom we believe will wholly embrace the new proposed name
of Lexaria Bioscience Corp.
Lexaria food products are available at www.vipova.com
and at www.lexariaenergyfoods.com
Lexaria is a food sciences company focused on
the delivery of active compounds that can behave as superfoods through its
proprietary infusion technologies. Lexaria s technology enables higher
bioavailability rates for CBD; THC; NSAIDs; Nicotine and other molecules than is
possible without lipophilic enhancement technology. This can allow for lower
overall dosing requirements and/or higher effectiveness in active molecule
delivery. Lexaria hopes to reduce other common but less healthy ingestion
methods such as smoking as it embraces the benefits of public health.
legal hemp oil extracts, grown from agricultural hemp in locations where it is
legal to do so, in ViPovaTM-branded tea, coffee, and hot chocolate.
ViPovaTM uses its patent-pending process to infuse concentrated
amounts of hemp oil within lipids, providing more bioactivity and comfort to the
body during the absorption process. Only ViPovaTM has this
ground-breaking technology for hemp oil/lipid infusion. www.vipova.com
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to:
laboratory test findings that the in vitro results provide evidence of
the future intestinal absorption enhancing capabilities of the technology, that
the Company may become a leader in the development of potentially a wide range
of product lines with enhanced gastro-intestinal absorption performance
capabilities, or that the technology will function in a similar manner if tested
with THC, nicotine, or any of the other molecules named in our patent
applications. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. Access to capital,
or lack thereof, is a major risk and there is no assurance that the Company will
be able to raise required working capital. Factors which could cause actual
results to differ materially from those estimated by the Company include, but
are not limited to, government regulation, managing and maintaining growth, the
effect of adverse publicity, litigation, competition, the patent application and
approval process and other factors which may be identified from time to time in
the Company's public announcements and filings. There is no assurance that the
hemp oil sector, or alternative health businesses will provide any benefit to
Lexaria, or that the Company will experience any growth through participation in
these sectors. There is no assurance that existing capital is sufficient for the
Company's needs or that it will be able to raise additional capital. There is no
assurance that any planned corporate activity, business venture, or initiative
will be pursued, or if pursued, will be successful. There is no assurance that
any hemp oil or cannabinoid-based product will promote, assist, or maintain any
beneficial human health conditions whatsoever. There is no assurance that any
patent application in the USA or any other nation or under any treaty will
result in the award of an actual patent; nor that an award of any actual patent
will protect against challenges from unknown third parties. There is no
assurance that any of Lexaria s postulated uses, benefits, or advantages for the
patent-pending technology will in fact be realized in any manner or in any part.
No statement herein has been evaluated by the Food and Drug Administration
(FDA). ViPovaTM products are not intended to diagnose, treat, cure or
prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.